Episode Details
Back to Episodes
Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering
Published 1 year, 4 months ago
Description
Chairman & CEO Emmanuel Savioz describes the benefits of decentralized manufacturing that is at or near the site of treatment. He highlights an armored-CAR AML program the company has with MSK in New York, and discusses Tigen's non-viral platform for NHL and multiple myeloma.